Beraprost’s Efficacy and Safety in the Treatment of Intermittent Claudicatio in Patients with Critical Limb Threatening Ischemia (CLTI)

Critical limb threatening ischemia (CLTI) is the most advanced stage of peripheral arterial diseases. Alternative treatment for claudication in CLTI patients is beraprost. We aim to review effectiveness and safety beraprost for relieve symptoms in CLTI. We conducted systematic literature searching u...

Full description

Saved in:
Bibliographic Details
Main Authors: Andhika Pangestu, Nur Asicha, Rahmat Cahyanur, Resultanti
Format: Article
Language:Indonesian
Published: Department of Internal Medicine, Faculty of Medicine Universitas Indonesia 2023-06-01
Series:Jurnal Penyakit Dalam Indonesia
Subjects:
Online Access:https://scholarhub.ui.ac.id/jpdi/vol10/iss2/6/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850160795041660928
author Andhika Pangestu
Nur Asicha
Rahmat Cahyanur
Resultanti
author_facet Andhika Pangestu
Nur Asicha
Rahmat Cahyanur
Resultanti
author_sort Andhika Pangestu
collection DOAJ
description Critical limb threatening ischemia (CLTI) is the most advanced stage of peripheral arterial diseases. Alternative treatment for claudication in CLTI patients is beraprost. We aim to review effectiveness and safety beraprost for relieve symptoms in CLTI. We conducted systematic literature searching using PubMed/MEDLINE, Embase, ProQuest, and Cochrane databases. Selected articles were examined for duplication and screened by abstract and title. Then, we appraised the articles based on the critical appraisal sheet from Centre for Evidence-Based Medicine (CEBM) University of Oxford. We found one systematic review-meta analysis (SR-MA) which involved 4,477 randomized participants. The results from this study are moderate quality evidence that prostanoids reduced rest pain (RR 1.30; 95%CI 1.06 – 1.59) and promoted ulcer healing (RR 1.24; 95%CI 1.04 – 1.48). In adult patients with CLTI and intermittent claudication as the primary complaint, vasodilator agents such as beraprost have a beneficial effect and a favorable therapeutic response. Numerous effects, including cardiovascular benefit, adverse events, resting pain relief, ulcer healing, outcome maximum walking distance (MWD), and pain-free walking distance, demonstrate the benefit (PFWD). The benefits of beraprost differ depending on the mechanism of action and pharmacokinetics of the drugs.
format Article
id doaj-art-3e63a38eae5b43c4b0238ad59c86b186
institution OA Journals
issn 2406-8969
2549-0621
language Indonesian
publishDate 2023-06-01
publisher Department of Internal Medicine, Faculty of Medicine Universitas Indonesia
record_format Article
series Jurnal Penyakit Dalam Indonesia
spelling doaj-art-3e63a38eae5b43c4b0238ad59c86b1862025-08-20T02:23:04ZindDepartment of Internal Medicine, Faculty of Medicine Universitas IndonesiaJurnal Penyakit Dalam Indonesia2406-89692549-06212023-06-0110296101https://doi.org/10.7454/jpdi.v10i2.1415Beraprost’s Efficacy and Safety in the Treatment of Intermittent Claudicatio in Patients with Critical Limb Threatening Ischemia (CLTI) Andhika Pangestu0Nur Asicha1Rahmat Cahyanur2Resultanti3Kelompok Staf Medis Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo, JakartaKelompok Staf Medis Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo, JakartaDivisi Hematologi dan Onkologi Medik, Kelompok Staf Medis Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/Rumah Sakit Umum Pusat Nasional Cipto Mangunkusumo, JakartaDivisi Kardiologi, Kelompok Staf Medis Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/Rumah Sakit Umum Pusat Nasional Cipto Mangunkusumo, JakartaCritical limb threatening ischemia (CLTI) is the most advanced stage of peripheral arterial diseases. Alternative treatment for claudication in CLTI patients is beraprost. We aim to review effectiveness and safety beraprost for relieve symptoms in CLTI. We conducted systematic literature searching using PubMed/MEDLINE, Embase, ProQuest, and Cochrane databases. Selected articles were examined for duplication and screened by abstract and title. Then, we appraised the articles based on the critical appraisal sheet from Centre for Evidence-Based Medicine (CEBM) University of Oxford. We found one systematic review-meta analysis (SR-MA) which involved 4,477 randomized participants. The results from this study are moderate quality evidence that prostanoids reduced rest pain (RR 1.30; 95%CI 1.06 – 1.59) and promoted ulcer healing (RR 1.24; 95%CI 1.04 – 1.48). In adult patients with CLTI and intermittent claudication as the primary complaint, vasodilator agents such as beraprost have a beneficial effect and a favorable therapeutic response. Numerous effects, including cardiovascular benefit, adverse events, resting pain relief, ulcer healing, outcome maximum walking distance (MWD), and pain-free walking distance, demonstrate the benefit (PFWD). The benefits of beraprost differ depending on the mechanism of action and pharmacokinetics of the drugs.https://scholarhub.ui.ac.id/jpdi/vol10/iss2/6/beraprostcltiintermittent claudicatio
spellingShingle Andhika Pangestu
Nur Asicha
Rahmat Cahyanur
Resultanti
Beraprost’s Efficacy and Safety in the Treatment of Intermittent Claudicatio in Patients with Critical Limb Threatening Ischemia (CLTI)
Jurnal Penyakit Dalam Indonesia
beraprost
clti
intermittent claudicatio
title Beraprost’s Efficacy and Safety in the Treatment of Intermittent Claudicatio in Patients with Critical Limb Threatening Ischemia (CLTI)
title_full Beraprost’s Efficacy and Safety in the Treatment of Intermittent Claudicatio in Patients with Critical Limb Threatening Ischemia (CLTI)
title_fullStr Beraprost’s Efficacy and Safety in the Treatment of Intermittent Claudicatio in Patients with Critical Limb Threatening Ischemia (CLTI)
title_full_unstemmed Beraprost’s Efficacy and Safety in the Treatment of Intermittent Claudicatio in Patients with Critical Limb Threatening Ischemia (CLTI)
title_short Beraprost’s Efficacy and Safety in the Treatment of Intermittent Claudicatio in Patients with Critical Limb Threatening Ischemia (CLTI)
title_sort beraprost s efficacy and safety in the treatment of intermittent claudicatio in patients with critical limb threatening ischemia clti
topic beraprost
clti
intermittent claudicatio
url https://scholarhub.ui.ac.id/jpdi/vol10/iss2/6/
work_keys_str_mv AT andhikapangestu beraprostsefficacyandsafetyinthetreatmentofintermittentclaudicatioinpatientswithcriticallimbthreateningischemiaclti
AT nurasicha beraprostsefficacyandsafetyinthetreatmentofintermittentclaudicatioinpatientswithcriticallimbthreateningischemiaclti
AT rahmatcahyanur beraprostsefficacyandsafetyinthetreatmentofintermittentclaudicatioinpatientswithcriticallimbthreateningischemiaclti
AT resultanti beraprostsefficacyandsafetyinthetreatmentofintermittentclaudicatioinpatientswithcriticallimbthreateningischemiaclti